Physician profile
Gabriel El-Kass
NPI 1821295353
$3,287.58
in general payments reported to CMS, 2019-2025
24 companies · $149 in 2025
The $149 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,627 · 2020: $597 · 2021: $215 · 2022: $91.52 · 2023: $269 · 2024: $340 · 2025: $149.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $758.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $757.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Angiodynamics, INC. | $1,483.33 | 2019-2020 | |
| Baxter Healthcare | $236.47 | 2020-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $174.73 | 2022-2024 | Livtencity, Gattex |
| W. L. Gore & Associates, INC. | $150.71 | 2022-2024 | Gore Viabahn Endoprosthesis, Gore Viabahn Vbx Balloon Expandable Endo |
| Vantive US Healthcare LLC | $149.33 | 2025 | Renal - Pd |
| Otsuka America Pharmaceutical, INC. | $139.35 | 2019 | |
| Covidien LP | $130.91 | 2020 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $101.06 | 2019 | |
| Amgen INC. | $88.86 | 2019-2022 | |
| Horizon Therapeutics Plc | $83.39 | 2023 | Krystexxa |
| Astrazeneca Pharmaceuticals LP | $79.96 | 2019-2022 | |
| Mallinckrodt Hospital Products INC. | $72.55 | 2021 | |
| Nxstage Medical, INC. | $72.20 | 2023 | Nxstage System One |
| Vifor Pharma, INC. | $48.74 | 2019-2021 | |
| Boston Scientific Corporation | $46.68 | 2019 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fresenius USA Marketing, INC. | $37.59 | 2019 | |
| Medtronic, INC. | $35.36 | 2021 | |
| Glaxosmithkline, LLC. | $34.19 | 2021-2023 | Benlysta |
| Bayer Healthcare Pharmaceuticals INC. | $30.74 | 2021-2022 | |
| Abbott Laboratories | $24.67 | 2024 | Absolute Pro |
| Lundbeck LLC | $23.73 | 2021 | |
| Bard Peripheral Vascular, INC. | $16.20 | 2023 | Lifestent Solo Vascular Stent |
| Travere Therapeutics, INC. | $15.69 | 2021 | |
| Opko Pharmaceuticals, LLC | $11.14 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gabriel El-Kass listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.